Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by movement dysfunction due to selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. Non-motor symptoms of PD (e.g., sensory dysfunction, sleep disturbance, constipation, neuropsychiatric symptoms) precede motor symptoms, appear at all stages, and impact the quality of life, but they frequently go unrecognized and remain untreated. Even when identified, traditional dopamine replacement therapies have little effect. We discuss here the pathology of two PD-associated non-motor symptoms: olfactory dysfunction and depression. Olfactory dysfunction is one of the earliest non-motor symptoms in PD and predates the onset of motor symptoms. It is accompanied by early deposition of Lewy pathology and neurotransmitter alterations. Because of the correlation between olfactory dysfunction and an increased risk of progression to PD, olfactory testing can potentially be a specific diagnostic marker of PD in the prodromal stage. Depression is a prevalent PD-associated symptom and is often associated with reduced quality of life. Although the pathophysiology of depression in PD is unclear, studies suggest a causal relationship with abnormal neurotransmission and abnormal adult neurogenesis. Here, we summarize recent progress in the pathology of the non-motor symptoms of PD, aiming to provide better guidance for its effective management.

Highlights

  • Parkinson’s disease (PD) is a progressive neurological disorder characterized by motor dysfunction that affects 10 million people globally, and this number is expected to double by 2030 (Dorsey et al 2007)

  • We summarize the current progress in two pathological features of PD–olfactory deficits and depression–to provide crucial insights into the requirements of early diagnosis and clearer recommendations for PD treatment

  • dopamine transporter (DAT) positron emission tomography (PET) shows a difference in correlation coefficients between olfactory testing score and DAT binding potential depending on the brain region; with a higher correlation for the hippocampus than the amygdala, ventral and dorsal striatum (Bohnen et al 2008a). These findings suggest that dopaminergic impairment in regions other than the olfactory bulb (OB) could be responsible for the olfactory dysfunction observed in patients with PD

Read more

Summary

Introduction

Parkinson’s disease (PD) is a progressive neurological disorder characterized by motor dysfunction that affects 10 million people globally, and this number is expected to double by 2030 (Dorsey et al 2007). The UPSIT scores of PD were strongly correlated with various motor and non-motor symptoms, such as anxiety, depression and sleep disturbances, as well as with the degree of nigrostriatal dopaminergic cell loss, indicating that olfactory assessment using UPSIT could be a potential diagnostic tool for predicting disease progression.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call